Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Invivyd, Inc. reported second quarter 2026 financial results featuring $14.3 million in net product revenue from PEMGARDA, a 21% increase year-over-year, driven by increased patient demand. The company completed enrollment in key Phase 3 clinical trials for its novel monoclonal antibody candidate VYD2311 targeting COVID-19, with top-line data antic…